Early Acne Improvements With Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel: What to Expect in the First 4 Weeks of Treatment

Julie C Harper, MD; Leon H Kircik, MD, MD; Michael Gold, MD; Adelaide A Hebert, MD; Jeffrey L Sugarman, MD, PhD; Lawrence Green, MD; Linda Stein Gold, MD; Hilary Baldwin, MD; James Q Del Rosso, DO; Eric Guenin, PharmD, PhD, MPh

Objectives

This 12-week study was designed to evaluate the effectiveness and tolerability of a fixed-dose acne treatment gel and its dyads in the treatment of facial acne lesions.

Methods

The study included a Phase 2 study and two Phase 3 studies, with 2,486 patients randomized to receive treatment with clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB), adapalene 0.15% gel (ADAP), or vehicle gel. Study participants were adults aged 16 to 70 years with mild to moderate facial acne lesions.

Results

Patients treated with CAB demonstrated greater reductions in inflammatory and noninflammatory lesions compared to their respective dyads and vehicle controls, with improvements seen as early as week 4. The percentage of participants with a one-third reduction in their inflammatory lesions at week 4 was significantly greater with CAB compared to the dyads and vehicle gel. Significant differences were also seen in the reduction of noninflammatory lesions.

Conclusions

Fixed-dose, triple-combination clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel was well tolerated, with rapid therapeutic effects. Acne lesion reductions were significantly greater with CAB compared to the dyads and vehicle gel, indicating that the additional product in the triple combination did not worsen tolerability. Cutaneous safety and tolerability assessments with CAB were better than BPO/adapalene, indicating that the additional product in the triple combination did not worsen tolerability.

ACKNOWLEDGMENTS: Medical writing support was provided by Prescript Medical Communications Group (Chicago, IL) with financial support from Ortho Dermatologics. Ortho Dermatologics is a division of Bausch Health US, LLC. Presented at 2024 Winter Clinical Dermatology Conference - Miami. February 16-18, 2024 - Miami Beach, FL.

REFERENCES


AUTHOR DISCLOSURES

Dr. Eric Guenin, PharmD, PhD, MPh: Consultant for: Almirall, Cassiopea, Foamix, Galderma, Ortho Dermatologics, Sol Gel, and Sun Pharma.

Dr. Julie C. Harper, MD: Consultant for: Almirall, Cassiopea, Foamix, Galderma, Ortho Dermatologics, Sol Gel, and Sun Pharma.

Dr. Leon H. Kircik, MD, MD: Consultant for: Almirall, Cassiopea, Foamix, Galderma, Ortho Dermatologics, Sol Gel, and Sun Pharma.

Dr. Michael Gold, MD: Consultant for: Almirall, Cassiopea, Foamix, Galderma, Ortho Dermatologics, Sol Gel, and Sun Pharma.

Dr. Adelaide A. Hebert, MD: Consultant for: Almiratt, Cassiopea, Foamix, Galderma, Ortho Dermatologics, Sol Gel, and Sun Pharma.

Dr. Jeffrey L. Sugarman, MD, PhD: Consultant for: Almiratt, Cassiopea, Foamix, Galderma, Ortho Dermatologics, Sol Gel, and Sun Pharma.

Dr. Lawrence Green, MD: Consultant for: Almiratt, Cassiopea, Foamix, Galderma, Ortho Dermatologics, Sol Gel, and Sun Pharma.

Dr. Linda Stein Gold, MD: Consultant for: Almiratt, Cassiopea, Foamix, Galderma, Ortho Dermatologics, Sol Gel, and Sun Pharma.

Dr. Hilary Baldwin, MD: Consultant for: Almiratt, Cassiopea, Foamix, Galderma, Ortho Dermatologics, Sol Gel, and Sun Pharma.

Dr. James Q. Del Rosso, DO: Consultant for: Almiratt, Cassiopea, Foamix, Galderma, Ortho Dermatologics, Sol Gel, and Sun Pharma.

Dr. Eric Guenin, PharmD, PhD, MPh: Employee of: Ortho Dermatologics.

Dr. Julie C. Harper, MD: Employee of: Ortho Dermatologics.

Dr. Leon H. Kircik, MD, MD: Employee of: Ortho Dermatologics.

Dr. Michael Gold, MD: Employee of: Ortho Dermatologics.

Dr. Adelaide A. Hebert, MD: Employee of: Ortho Dermatologics.

Dr. Jeffrey L. Sugarman, MD, PhD: Employee of: Ortho Dermatologics.

Dr. Lawrence Green, MD: Employee of: Ortho Dermatologics.

Dr. Linda Stein Gold, MD: Employee of: Ortho Dermatologics.

Dr. Hilary Baldwin, MD: Employee of: Ortho Dermatologics.

Dr. James Q. Del Rosso, DO: Employee of: Ortho Dermatologics.

Dr. Eric Guenin, PharmD, PhD, MPh: Stock Options in: Ortho Dermatologics.

Dr. Julie C. Harper, MD: Stock Options in: Ortho Dermatologics.

Dr. Leon H. Kircik, MD, MD: Stock Options in: Ortho Dermatologics.

Dr. Michael Gold, MD: Stock Options in: Ortho Dermatologics.

Dr. Adelaide A. Hebert, MD: Stock Options in: Ortho Dermatologics.

Dr. Jeffrey L. Sugarman, MD, PhD: Stock Options in: Ortho Dermatologics.

Dr. Lawrence Green, MD: Stock Options in: Ortho Dermatologics.

Dr. Linda Stein Gold, MD: Stock Options in: Ortho Dermatologics.

Dr. Hilary Baldwin, MD: Stock Options in: Ortho Dermatologics.

Dr. James Q. Del Rosso, DO: Stock Options in: Ortho Dermatologics.

Dr. Eric Guenin, PharmD, PhD, MPh: Research Funding from: Almiratt, Cassiopea, Foamix, Galderma, Ortho Dermatologics, Sol Gel, and Sun Pharma.

Dr. Julie C. Harper, MD: Research Funding from: Almiratt, Cassiopea, Foamix, Galderma, Ortho Dermatologics, Sol Gel, and Sun Pharma.